A-101 Topical Solution
DrugA-101 Topical Solution applied Day 1, Day 15 and Day 29
NCT Number: NCT03487588
This study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.
Looking for future studies?
Notify Me30 year–75 year
All sexes
Interventional
Phase 4
Aclaris Investigational Site, Fort Washington, Pennsylvania, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A-101 Topical Solution applied Day 1, Day 15 and Day 29
Time frame: Day 113
Subject Satisfaction Questionnaire after treatment with A-101 Topical Solution
Time frame: Day 113
Effectiveness of treatment as measured by the Physician Lesion Assessment scale. The Physician Lesion Assessment Scale (PLA) is a 4 point scale used by the investigator to assess each subjects SK lesion. PLA=0 (Clear);PLA=1 (Near Clear; not elevated); PLA=2 (Thin;thickness </= 1 mm); PLA=3 (Thick; thickness > 1 mm).
Time frame: Day 113
Effectiveness of treatment assessed by PLA (4-point scale) compared to subject reported satisfaction with treatment. The PLA scale is a 4 point scale used by the investigator to assess each subject's SK lesion.
Aclaris Therapeutics, Inc.
Industry
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Acronym: SK-FAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07334600
Keratosis, Keratosis, Seborrheic
Medan, North Sumatra, Indonesia
View Trial DetailsNCT06046144
Basal Cell Carcinoma, Carcinoma
Saint-Etienne, France
View Trial DetailsNCT04229277
Basal Cell Carcinoma, Carcinoma
Copenhagen, Denmark
View Trial DetailsNCT03846531
Keratosis, Keratosis, Seborrheic
San Mateo, California, United States
View Trial Details